GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » Cyclically Adjusted Revenue per Share

GlaxoSmithKline Pakistan (KAR:GLAXO) Cyclically Adjusted Revenue per Share : ₨142.63 (As of Mar. 2025)


View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GlaxoSmithKline Pakistan's adjusted revenue per share for the three months ended in Mar. 2025 was ₨48.922. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₨142.63 for the trailing ten years ended in Mar. 2025.

During the past 12 months, GlaxoSmithKline Pakistan's average Cyclically Adjusted Revenue Growth Rate was 10.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GlaxoSmithKline Pakistan was 9.50% per year. The lowest was 9.50% per year. And the median was 9.50% per year.

As of today (2025-05-29), GlaxoSmithKline Pakistan's current stock price is ₨385.68. GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₨142.63. GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio of today is 2.70.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlaxoSmithKline Pakistan was 3.13. The lowest was 0.58. And the median was 1.08.


GlaxoSmithKline Pakistan Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pakistan Cyclically Adjusted Revenue per Share Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 105.34 115.87 125.01 138.34

GlaxoSmithKline Pakistan Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.71 132.44 135.14 138.34 142.63

Competitive Comparison of GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio falls into.


;
;

GlaxoSmithKline Pakistan Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GlaxoSmithKline Pakistan's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=48.922/134.9266*134.9266
=48.922

Current CPI (Mar. 2025) = 134.9266.

GlaxoSmithKline Pakistan Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 18.647 100.684 24.989
201509 18.252 100.392 24.531
201512 19.849 99.792 26.837
201603 19.193 100.470 25.775
201606 21.498 101.688 28.525
201609 21.766 101.861 28.832
201612 24.223 101.863 32.086
201703 26.342 102.862 34.553
201706 24.594 103.349 32.109
201709 24.077 104.136 31.196
201712 27.918 104.011 36.216
201803 28.645 105.290 36.708
201806 25.343 106.317 32.163
201809 25.293 106.507 32.042
201812 27.421 105.998 34.905
201903 26.276 107.251 33.057
201906 29.078 108.070 36.304
201909 25.653 108.329 31.951
201912 33.777 108.420 42.035
202003 25.227 108.902 31.256
202006 24.319 108.767 30.168
202009 33.990 109.815 41.763
202012 26.706 109.897 32.788
202103 24.158 111.754 29.167
202106 28.443 114.631 33.479
202109 30.827 115.734 35.939
202112 31.664 117.630 36.320
202203 27.086 121.301 30.129
202206 29.963 125.017 32.338
202209 37.703 125.227 40.623
202212 36.888 125.222 39.747
202303 35.794 127.348 37.924
202306 37.242 128.729 39.035
202309 43.409 129.860 45.103
202312 39.663 129.419 41.351
202403 49.035 131.776 50.207
202406 41.621 132.554 42.366
202409 46.246 133.029 46.906
202412 55.220 133.157 55.954
202503 48.922 134.927 48.922

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


GlaxoSmithKline Pakistan  (KAR:GLAXO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GlaxoSmithKline Pakistan's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=385.68/142.63
=2.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GlaxoSmithKline Pakistan was 3.13. The lowest was 0.58. And the median was 1.08.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GlaxoSmithKline Pakistan Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Pakistan Business Description

Traded in Other Exchanges
N/A
Address
35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines